(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International Publication Date
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number
WO 02/02552 A1

(51) **International Patent Classification**[7]: C07D 405/04, 417/04, 471/04, A61K 31/517, 31/519, A61P 17/06, 35/00 // (C07D 471/04, 239:00, 221:00)

(21) **International Application Number:** PCT/US01/20706

(22) **International Filing Date:** 28 June 2001 (28.06.2001)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**

60/215,508	30 June 2000 (30.06.2000)	US
60/271,845	27 February 2001 (27.02.2001)	US

(71) **Applicant** *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB], Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 ONN (GB)

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **MCCLURE, Michael Scott,** [US/US], GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US) **OSTERHOUT, Martin Howard,** [US/US], GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US) **ROSCHANGAR, Frank** [DE/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US) **SACCHETTI, Mark Joseph,** [US/US], GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(74) **Agents: LEMANOWICZ, John L.,** et al., GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US)

(81) **Designated States** *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

(84) **Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

G00001

WO 02/02552 A1

(54) **Title:** QUINAZOLINE DITOSYLATE SALT COMPOUNDS

(57) **Abstract:** Ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity.